Is the new COVID-19 pill really a game changer?
Virologist Dr Vinod Balasubramaniam explains the interim trial results of the therapy in patients with mild to moderate disease.
The Federal Government has announced it has bought 300,000 doses of a new COVID-19 treatment called molnupiravir.
It has yet to be approved by the TGA, but last week Merck, the company behind the drug, released an interim analysis of an ongoing phase III trial in patients with mild to moderate COVID-19.
The results have yet to be peer-reviewed.
Dr Vinod Balasubramaniam (PhD), a virologist at the Jeffrey Cheah School of Medicine and Health Sciences at Monash University in Malaysia, explains to the Australian Science Media Centre what the drug is, how it works and what the clinical trials are suggesting in terms of efficacy.
